Which radiation dose is best for prostate cancer? new trial aims to find out

NCT ID NCT03827616

Ongoing Disease control Sponsor: Tatarstan Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial compares two common radiotherapy schedules for prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. Both are already used in clinics, but it is not clear which one works better or causes fewer side effects. The study involves 400 men with early-stage prostate cancer and will track cancer recurrence over 5 to 10 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (hypofractionated intensity-modulated radiotherapy using helical tomotherapy)
What this could lead to: If this trial succeeds, it could help doctors choose the best radiotherapy schedule for prostate cancer, improving cancer control and reducing side effects.
What could go wrong: This is a phase 2 trial, so results are not definitive. Both schedules are already standard, so the difference may be small, and long-term outcomes are still being tracked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENITAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENITAL NEOPLASMS PROSTATIC NEOPLASMS

Contacts and locations

Locations

Tatarstan Cancer Cente

Kazan', Tatarstan Republic, 420029, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.